Intelligence Briefing · ~3 min read
Crescent Pharma Faces Significant Risks from Ramipril Recall in Competitive Landscape
Cardiovascular · ACE Inhibitor
Type
Executive BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
6
Key Takeaways
Leadership-ready summary — read in 3 minutes.
- The recall of Ramipril 10mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market share in the cardiovascular segment. Portfolio teams must closely monitor the situation to assess potential impacts on sales and develop strategies to mitigate reputational damage. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 20 ranked evidence items (3 high-relevance).
- Elevated medium regulatory exposure for Crescent Pharma Limited could delay market entry or constrain labeling if agency review intensifies.
- Signal severity is high — leadership review is warranted.
- This recall could lead to a decline in sales for Crescent Pharma, affecting their competitive positioning within the ACE inhibitors market.
Why It Matters
Strategic context for leadership and portfolio decision-making.
The recall of Ramipril 10mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market share in the cardiovascular segment. Portfolio teams must closely monitor the situation to assess potential impacts on sales and develop strategies to mitigate reputational damage. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 20 ranked evidence items (3 high-relevance).
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error
Cardiovascular · ACE Inhibitor
Source: Safety Signal
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error
Cardiovascular · ACE Inhibitor
Insights
- Crescent Pharma Faces Significant Risks from Ramipril Recall in Competitive Landscape
Cardiovascular · ACE Inhibitor